Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

H. pylori colonic neoplasm link confirmed

Helicobacter pylori gastritis is significantly associated with colonic neoplasms, show the results of one of the largest studies of the association to date.

6 Dec 2012

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

6 Dec 2012

Study provides important data about fertility window of women with childhood cancer

This study provided important data about the fertility window of women who had suffered from childhood cancer and information concerning the associated risk factors, but did not confirm the greater risk of premature menopause (before the age of 40) that was reported by the American studies.

5 Dec 2012

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

Disabling ItpkB enzyme improves function of Natural Killer cells

Researchers at The Scripps Research Institute (TRSI) are fueling the future of cancer treatment by improving a powerful tool in disease defense: the body's immune system. By revealing a novel but widespread cell signaling process, the scientists may have found a way to manipulate an important component of the immune system into more effectively fighting disease.

29 Nov 2012

Watch out for Sjögren's syndrome in dry eye

Clinicians with patients who have clinically significant dry eye should be on the alert for underlying Sjögren's syndrome, report researchers in the British Journal of Ophthalmology.

28 Nov 2012

Weill Cornell Medical College dean wins Argentina's Dr. Luis Federico Leloir Prize

Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the Dr. Luis Federico Leloir Prize of International Cooperation in Science, Technology and Innovation from Argentina's Ministry of Science, Technology and Productive Innovation.

27 Nov 2012

Nonfunctional MED12 gene linked to chemotherapy resistance

Research published in Cell shows that people with tumors that have a nonfunctional version of the mediator 12 gene are resistant to drugs used to treat lung and colon cancer such as gefitinib.

26 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

A pathway called the "Unfolded Protein Response," or UPR, a cell's way of responding to unfolded and misfolded proteins, helps tumor cells escape programmed cell death during the development of lymphoma.

21 Nov 2012

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Gabrielle's Angel Foundation for Cancer Research today announced grant recipients of its first-ever Collaborative Research grant program. The inaugural awards total $800,000 for two groundbreaking research initiatives that span the medical capitals of New York, Boston and Chicago.

21 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Close monitoring needed in year after traumatic brain injury

Patients are at particularly high risk for developing epilepsy during the first year after traumatic brain injury, a study shows.

9 Nov 2012

SCCA to raise awareness about importance of lung cancer screening

Lung cancer is the No. 1 cause of cancer deaths in the United States, despite the fact it is largely preventable. For people at high risk of developing lung cancer, such as current or former longtime smokers, screening for the disease with low-dose CT scans is now a viable option that has been shown to significantly reduce mortality rates. In conjunction with National Lung Cancer Awareness Month, Seattle Cancer Care Alliance (SCCA) wants to raise awareness about the importance of prevention and early detection for at-risk populations.

9 Nov 2012

Canine lymphoma treatment adds up to cystitis

High cumulative doses of the alkylator cyclophosphamide could be to blame for the development of sterile hemorrhagic cystitis in dogs being treated for lymphoma, indicate the results of a US study.

8 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Lymphoma News and Research

Further Reading

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

H. pylori colonic neoplasm link confirmed

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Study provides important data about fertility window of women with childhood cancer

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Disabling ItpkB enzyme improves function of Natural Killer cells

Watch out for Sjögren's syndrome in dry eye

Weill Cornell Medical College dean wins Argentina's Dr. Luis Federico Leloir Prize

Nonfunctional MED12 gene linked to chemotherapy resistance

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Close monitoring needed in year after traumatic brain injury

SCCA to raise awareness about importance of lung cancer screening

Canine lymphoma treatment adds up to cystitis

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News